The company’s operational results are divided in two revenue segments. These are Actavis Pharma and Anda Distribution. The Actavis Pharma segment represents all branded, branded generic, generic and over-the-counter pharmaceutical products whereas Anda Distribution revenue includes distributing third-party products primarily to independent pharmacies, pharmacy chains and pharmacy buying groups.
Significant growth in the North American pharma market segment was due to recent acquisitions as well as new product launches. Net revenue increased 31 percent to $2.24 billion for the second quarter 2014, due to the acquisition of Warner Chilcott and their therapeutic portfolio. These include: women’s healthcare, urology & gastroenterology, dermatology and other established brands. Actavis’ generics division also saw an increase of 9 percent to 1.03 billion for the 2014 second quarter. The recent product launches of the generic versions of Cymbalta® and Lidoderm® were key contributors.
The Anda segment saw an increase of an astounding 55 percent to $427 million, compared to $275.8 million in the second quarter 2013.
"Our exceptional performance during the second quarter resulted from double digit revenue growth in both our North American brand and generics businesses and Anda Distribution,"
"Overall revenue growth of 31 percent in our commercial pharmaceutical business was supported by our North American Brands business, which benefitted from the expanded portfolio resulting from the acquisition of Warner Chilcott in October 2013, as well as continued strong sales of core products in the U.S. We also saw strong growth within our generics business, powered by our strong base business along with continued strong sales of the generic versions of Lidoderm® and Cymbalta®. Revenue in our international operations reflected the divestiture of our generics commercial operations in seven markets in Western Europe to Aurobindo Pharma Limited in April 2014."
With the recent acquisition of Forest Laboratories in July the company expects to see annual revenue amounting to more than $15 billion for 2015.
With such industry leaders posting gains in profitability from their successful product pipeline, they will need both certified and qualified individuals to promote their diversified therapeutic portfolio. When industry leaders look for new candidates for sales/marketing positions, they look toward individuals that are industry trained. Companies are looking for people that have the background to market their product both proficiently and efficiently.
CANDIDATES WHO WANT TO BREAK INTO PHARMACEUTICAL SALES!
The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals. The CNPR examination is dedicated to increasing the professional level of NAPSR members and to developing meaningful and ethical standards fully accepted by both its members and members of the pharmaceutical community.
The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Pharmaceutical sales candidates who have this training will differentiate themselves from other individuals looking for open positions. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®. CNPR® graduates should immediately utilize the NAPSRx® Career Center to apply for pharmaceutical sales positions.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives (NAPSRx) for more information.